Valion Bio, Inc. operates as a late-stage immunotherapeutics company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod ...
Q1 2026
May 14, 2026
FY 2025
Mar 30, 2026
Q4 2025
Q3 2025
Nov 14, 2025
Q2 2025
Aug 14, 2025